S&P 500   5,136.45 (-0.01%)
DOW   39,010.22 (-0.20%)
QQQ   444.67 (-0.21%)
AAPL   173.86 (-3.23%)
MSFT   415.49 (+0.00%)
META   501.69 (-0.12%)
GOOGL   132.55 (-3.35%)
AMZN   178.24 (+0.01%)
TSLA   187.56 (-7.44%)
NVDA   866.50 (+5.31%)
NIO   5.34 (-7.61%)
AMD   206.86 (+2.08%)
BABA   71.87 (-3.69%)
T   16.80 (-1.06%)
F   12.86 (+3.29%)
MU   96.67 (+1.60%)
CGC   3.01 (-6.23%)
GE   160.45 (+1.13%)
DIS   113.76 (+1.62%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.71 (-1.37%)
XOM   104.57 (-1.20%)
S&P 500   5,136.45 (-0.01%)
DOW   39,010.22 (-0.20%)
QQQ   444.67 (-0.21%)
AAPL   173.86 (-3.23%)
MSFT   415.49 (+0.00%)
META   501.69 (-0.12%)
GOOGL   132.55 (-3.35%)
AMZN   178.24 (+0.01%)
TSLA   187.56 (-7.44%)
NVDA   866.50 (+5.31%)
NIO   5.34 (-7.61%)
AMD   206.86 (+2.08%)
BABA   71.87 (-3.69%)
T   16.80 (-1.06%)
F   12.86 (+3.29%)
MU   96.67 (+1.60%)
CGC   3.01 (-6.23%)
GE   160.45 (+1.13%)
DIS   113.76 (+1.62%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.71 (-1.37%)
XOM   104.57 (-1.20%)
S&P 500   5,136.45 (-0.01%)
DOW   39,010.22 (-0.20%)
QQQ   444.67 (-0.21%)
AAPL   173.86 (-3.23%)
MSFT   415.49 (+0.00%)
META   501.69 (-0.12%)
GOOGL   132.55 (-3.35%)
AMZN   178.24 (+0.01%)
TSLA   187.56 (-7.44%)
NVDA   866.50 (+5.31%)
NIO   5.34 (-7.61%)
AMD   206.86 (+2.08%)
BABA   71.87 (-3.69%)
T   16.80 (-1.06%)
F   12.86 (+3.29%)
MU   96.67 (+1.60%)
CGC   3.01 (-6.23%)
GE   160.45 (+1.13%)
DIS   113.76 (+1.62%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.71 (-1.37%)
XOM   104.57 (-1.20%)
S&P 500   5,136.45 (-0.01%)
DOW   39,010.22 (-0.20%)
QQQ   444.67 (-0.21%)
AAPL   173.86 (-3.23%)
MSFT   415.49 (+0.00%)
META   501.69 (-0.12%)
GOOGL   132.55 (-3.35%)
AMZN   178.24 (+0.01%)
TSLA   187.56 (-7.44%)
NVDA   866.50 (+5.31%)
NIO   5.34 (-7.61%)
AMD   206.86 (+2.08%)
BABA   71.87 (-3.69%)
T   16.80 (-1.06%)
F   12.86 (+3.29%)
MU   96.67 (+1.60%)
CGC   3.01 (-6.23%)
GE   160.45 (+1.13%)
DIS   113.76 (+1.62%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.71 (-1.37%)
XOM   104.57 (-1.20%)
NASDAQ:ALLR

Allarity Therapeutics (ALLR) Stock Price, News & Analysis

$0.42
+0.01 (+1.51%)
(As of 01:27 PM ET)
Today's Range
$0.41
$0.42
50-Day Range
$0.38
$0.57
52-Week Range
$0.38
$320.60
Volume
89,422 shs
Average Volume
118,694 shs
Market Capitalization
$2.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ALLR stock logo

About Allarity Therapeutics Stock (NASDAQ:ALLR)

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

ALLR Stock Price History

ALLR Stock News Headlines

Allarity Therapeutics to Present at Biomarkers 2024
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Allarity Therapeutics CEO James Cullem Steps Down
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
ALLR: Stenoparib Clinical Update
Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?
Allarity Therapeutics Inc ALLR
Pre-market Movers: ICCT, NCNC, ALLR, LYRA, MYNZ…
ALLR: IXEMPRA Clinical Update
See More Headlines
Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/04/2024
Next Earnings (Estimated)
3/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALLR
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-19,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($8.60) per share

Miscellaneous

Free Float
4,821,000
Market Cap
$2.02 million
Optionable
Not Optionable
Beta
0.24
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thomas H. Jensen (Age 46)
    Founder, CEO, Senior VP of Investor Relations & Director
  • Ms. Joan Y. Brown (Age 71)
    Interim CFO
    Comp: $180k
  • Dr. Marie Foegh DrSc (Age 81)
    M.D., Chief Medical Officer
    Comp: $340.31k
  • Mr. Peter Buhl Jensen Adj Professor (Age 69)
    M.D., M.D., Ph.D., Ph.D., Co-Founder
    Comp: $546.08k
  • Dr. Steen Meier Knudsen Ph.D. (Age 63)
    Founder & Chief Scientific Officer
    Comp: $185.11k














ALLR Stock Analysis - Frequently Asked Questions

How have ALLR shares performed in 2024?

Allarity Therapeutics' stock was trading at $0.5511 at the beginning of the year. Since then, ALLR stock has decreased by 24.5% and is now trading at $0.4160.
View the best growth stocks for 2024 here
.

When is Allarity Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 8th 2024.
View our ALLR earnings forecast
.

When did Allarity Therapeutics' stock split?

Allarity Therapeutics shares reverse split on Thursday, June 29th 2023. The 1-40 reverse split was announced on Thursday, June 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALLR) was last updated on 3/4/2024 by MarketBeat.com Staff